These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

929 related articles for article (PubMed ID: 30841523)

  • 41. Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers.
    Baldassarre T; Truesdell P; Craig AW
    Breast Cancer Res; 2017 Oct; 19(1):110. PubMed ID: 28974266
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Trastuzumab emtansine (Kadcyla(®)) approval in HER2-positive metastatic breast cancers].
    Guerin M; Sabatier R; Gonçalves A
    Bull Cancer; 2015 Apr; 102(4):390-7. PubMed ID: 25790739
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety Evaluation of Trastuzumab Emtansine in Japanese Patients with HER2-Positive Advanced Breast Cancer.
    Watanabe J; Ito Y; Saeki T; Masuda N; Takano T; Takao S; Nakagami K; Tsugawa K; Nakagawa S; Kanatani K; Nakayama T
    In Vivo; 2017; 31(3):493-500. PubMed ID: 28438884
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Chemotherapy and 2 or More HER2-Targeted Agents: Results From the T-PAS Expanded Access Study.
    Yardley DA; Krop IE; LoRusso PM; Mayer M; Barnett B; Yoo B; Perez EA
    Cancer J; 2015; 21(5):357-64. PubMed ID: 26389758
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Emerging Therapeutic Options for HER2-Positive Breast Cancer.
    Martin M; López-Tarruella S
    Am Soc Clin Oncol Educ Book; 2016; 35():e64-70. PubMed ID: 27249772
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1.
    Indira Chandran V; Månsson AS; Barbachowska M; Cerezo-Magaña M; Nodin B; Joshi B; Koppada N; Saad OM; Gluz O; Isaksson K; Borgquist S; Jirström K; Nabi IR; Jernström H; Belting M
    Mol Cancer Res; 2020 Apr; 18(4):644-656. PubMed ID: 31900313
    [TBL] [Abstract][Full Text] [Related]  

  • 47. ARX788, a Site-specific Anti-HER2 Antibody-Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1-resistant Breast and Gastric Cancers.
    Skidmore L; Sakamuri S; Knudsen NA; Hewet AG; Milutinovic S; Barkho W; Biroc SL; Kirtley J; Marsden R; Storey K; Lopez I; Yu W; Fang SY; Yao S; Gu Y; Tian F
    Mol Cancer Ther; 2020 Sep; 19(9):1833-1843. PubMed ID: 32669315
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Use and outcomes of targeted therapies in early and metastatic HER2-positive breast cancer in Australia: protocol detailing observations in a whole of population cohort.
    Daniels B; Lord SJ; Kiely BE; Houssami N; Haywood P; Lu CY; Ward RL; Pearson SA;
    BMJ Open; 2017 Jan; 7(1):e014439. PubMed ID: 28119394
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+ metastatic breast cancer.
    Niculescu-Duvaz I
    Curr Opin Mol Ther; 2010 Jun; 12(3):350-60. PubMed ID: 20521224
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nodular Regenerative Hyperplasia Induced by Trastuzumab Emtansine: Role of Emtansine?
    Lepelley M; Allouchery M; Long J; Boucherle D; Ranchoup Y; Le Marc'Hadour F; Villier C; Sturm N
    Ann Hepatol; 2018 Oct; 17(6):1067-1071. PubMed ID: 30600283
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy.
    Li JY; Perry SR; Muniz-Medina V; Wang X; Wetzel LK; Rebelatto MC; Hinrichs MJ; Bezabeh BZ; Fleming RL; Dimasi N; Feng H; Toader D; Yuan AQ; Xu L; Lin J; Gao C; Wu H; Dixit R; Osbourn JK; Coats SR
    Cancer Cell; 2016 Jan; 29(1):117-29. PubMed ID: 26766593
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Corneal Changes in Trastuzumab Emtansine Treatment.
    Kreps EO; Derveaux T; Denys H
    Clin Breast Cancer; 2018 Aug; 18(4):e427-e429. PubMed ID: 29615304
    [No Abstract]   [Full Text] [Related]  

  • 53. Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer.
    Najjar MK; Manore SG; Regua AT; Lo HW
    Genes (Basel); 2022 Nov; 13(11):. PubMed ID: 36360302
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Targeted Agents for HER2-Positive Breast Cancer: Optimal Use in Older Patients.
    Singh JC; Lichtman SM
    Drugs Aging; 2015 Dec; 32(12):975-82. PubMed ID: 26645293
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis.
    Diéras V; Harbeck N; Budd GT; Greenson JK; Guardino AE; Samant M; Chernyukhin N; Smitt MC; Krop IE
    J Clin Oncol; 2014 Sep; 32(25):2750-7. PubMed ID: 25024070
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Trastuzumab emtansine in breast cancer.
    Dirix LY; Rutten A; Huget P; Dirix M
    Expert Opin Biol Ther; 2013 Apr; 13(4):607-14. PubMed ID: 23477731
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of Ado-Trastuzumab Emtansine and Fam-Trastuzumab Deruxtecan on Metastatic Breast Cancer Harboring HER2 Amplification and the L755S Mutation.
    Mukohara T; Hosono A; Mimaki S; Nakayama A; Kusuhara S; Funasaka C; Nakao T; Fukasawa Y; Kondoh C; Harano K; Naito Y; Matsubara N; Tsuchihara K; Kuwata T
    Oncologist; 2021 Aug; 26(8):635-639. PubMed ID: 33559918
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer.
    Le QA; Bae YH; Kang JH
    Breast Cancer Res Treat; 2016 Oct; 159(3):565-73. PubMed ID: 27572338
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer.
    Krop IE; Suter TM; Dang CT; Dirix L; Romieu G; Zamagni C; Citron ML; Campone M; Xu N; Smitt M; Gianni L
    J Clin Oncol; 2015 Apr; 33(10):1136-42. PubMed ID: 25713436
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial.
    Li BT; Shen R; Buonocore D; Olah ZT; Ni A; Ginsberg MS; Ulaner GA; Offin M; Feldman D; Hembrough T; Cecchi F; Schwartz S; Pavlakis N; Clarke S; Won HH; Brzostowski EB; Riely GJ; Solit DB; Hyman DM; Drilon A; Rudin CM; Berger MF; Baselga J; Scaltriti M; Arcila ME; Kris MG
    J Clin Oncol; 2018 Aug; 36(24):2532-2537. PubMed ID: 29989854
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 47.